VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | LOTIS-2: R/R DLBCL patient characteristics impact DoR to loncastuximab tesirine

Paolo Caimi, MD, University Hospitals Cleveland Medical Center & Case Western Reserve University, Cleveland, OH, outlines the results of subgroup analysis of the Phase II LOTIS-2 trial (NCT03589469), investigating the association between duration of response (DoR) to loncastuximab tesirine and demographic and clinical characteristics in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Caimi reports that patients in different subgroups of risk had comparable outcomes with regards to DoR. The total population had an overall response rate of 48.3% with a complete response rate of 24.8%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Transcript (edited for clarity)

So, this is an update on the subgroup analysis from LOTIS-2. LOTIS-2 was a Phase II study, lending to the patient with relapsed/refrac-, relapse and refractory diffuse large B-cell lymphoma after at least two lines of therapy. It was a trial that included multiple different subtypes, or subgroups of diffuse large-B including some of those with high-risk.

And in this abstract, we updated the outcomes by subgroup and including patients with advanced age, as those who are older than 75 years of age, those with high-grade B-cell lymphoma, those with double- and triple-hit lymphoma, and those with a history of a previous transplant, or previous transformed lymphoma...

So, this is an update on the subgroup analysis from LOTIS-2. LOTIS-2 was a Phase II study, lending to the patient with relapsed/refrac-, relapse and refractory diffuse large B-cell lymphoma after at least two lines of therapy. It was a trial that included multiple different subtypes, or subgroups of diffuse large-B including some of those with high-risk.

And in this abstract, we updated the outcomes by subgroup and including patients with advanced age, as those who are older than 75 years of age, those with high-grade B-cell lymphoma, those with double- and triple-hit lymphoma, and those with a history of a previous transplant, or previous transformed lymphoma.

The main important component of the study was that this antibody-drug immunoconjugate that was given every three weeks until the response continued. And then, in terms of the responses, moves to what we observed was that the subgroups of different high-risk disease had a similar response, and similar duration of response, compared to the general group. So, high-risk groups had comparable outcomes without clear increase in toxicity for those who are older, or who had more advanced disease.

We did observe that the total population had an observed response rate of 48%, with a complete response rate of up to 23.4% partial response. The median duration responses for the, 70 responsers, 70 responders was 13.4 months, but they had not been reached for patients with complete remission. Those with double- or triple-hit had a median duration response that had not been reached, as well as for patients with advanced stage disease, the median duration of response was 12.6 months.

For patients that had older age, over 75, those were responding and had not reached a median duration of response, and those who were younger than 65 had a median duration response of 12.6 months. So, in general, patients who were higher risk had comparable outcomes to the general trial group.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter